Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
SRZN vs MNOV: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
SRZN Captures Overall Composite Edge (36.0 SELL vs 50.2 HOLD), While MNOV Leads 3–2 on Growth & Valuation Pillars
SRZN Overall Winner
6-Pillar Tally: SRZN 2 – 3 MNOV (1 Tie)
Matrix Metrics: SRZN 4 – 5 MNOV
As of Nov 20, 2026, Surrozen, Inc. Common (SRZN) captures the overall head-to-head institutional edge over Medicinova, Inc. (MNOV) on higher Unified Composite conviction (36.0/100 SELL vs. 50.2/100 HOLD) after splitting the core matrix 4–5 (led by Growth & Scale, Options & Positioning), while MNOV wins 3–2 across the 6-pillar growth and valuation breakdown. SRZN trades at $28.46 (N/M Forward P/E, -485.4% operating margin) versus MNOV at $1.31 (8.5x Forward P/E, -1232.2% operating margin).
- Composite vs. Pillar Nuance: While MNOV currently prints a higher short-term Unified Composite Score (50.2/100 HOLD vs. SRZN 36.0/100 SELL), SRZN captures the overall institutional head-to-head verdict (4–5 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (-485.4% vs. -1232.2% operating margin) and revenue trajectory (+408.6% vs. +12.4% YoY).
- Technical & Structure Timing Caution: SRZN trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 47.2); meanwhile MNOV is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About SRZN vs MNOV
SRZN
Head-to-Head Winner
Surrozen, Inc. Common
$28.46
-7.21% 1D
Market Cap
$642.7M
TTM Revenue
$11M
Forward P/E
N/M
Beta / 30D Vol
1.29β · 73% Vol
Unified Composite Score
36.0
SELL
Tech 15.0
Fund 42.0
Flow 65.0
Mom 50.0
Weinstein Technical Phase
Neutral · Hold
MNOV
Medicinova, Inc.
$1.31
+3.15% 1D
Market Cap
$65.1M
TTM Revenue
$935,717
Forward P/E
8.5x
Beta / 30D Vol
0.59β · 38% Vol
Unified Composite Score
50.2
HOLD
Tech 47.0
Fund 46.0
Flow 63.0
Mom 64.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (SRZN 2 – 3 MNOV)
1. Valuation Multiples
MNOV
Forward P/E
N/M
8.5x
Trailing P/E
N/M
8.5x
PEG Ratio
N/M
N/M
EV / Revenue
52.1x
42.5x
2. Growth & Scale
SRZN
Revenue Growth (YoY)
+408.6%
+12.4%
Earnings Growth (YoY)
-37.0%
+0.0%
TTM Revenue (USD)
$11M
$935,717
Market Cap
$642.7M
$65.1M
3. Profitability & Quality
MNOV
Gross Margin
N/A
42.2%
Operating Margin
-485.4%
-1232.2%
Net Profit Margin
0.0%
0.0%
Return on Equity (ROE)
-62.8%
-24.8%
4. Balance Sheet & Cash Flow
MNOV
Cash Generation (TTM)
-$31M
-$9.1M
Cash Flow Margin
N/A
N/A
Net Cash / Leverage
$95M Net Cash
$25M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
SRZN
Options Structure Phase
CONSOLIDATION
UNCLASSIFIED
Current IV / %ile
72.0% (13th %ile)
140.1% (50th %ile)
Put/Call OI Skew
21.00x (Put-Skewed)
N/A
OBV Trend / Tech Phase
NEUTRAL · Neutral
NEUTRAL · Markdown
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: SRZN (4) vs MNOV (5)| Institutional Metric | SRZN | MNOV | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $642.7M | $65.1M | SRZN | |
| Trailing P/E Ratio | N/M | 8.5x | MNOV | |
| Forward P/E Ratio | N/M | 8.5x | MNOV | |
| Revenue Growth (YoY) | +408.6% | +12.4% | SRZN | |
| Operating Margin (TTM) | -485.4% | -1232.2% | SRZN | |
| Net Profit Margin | 0.0% | 0.0% | Tie | |
| Return on Equity (ROE) | -62.8% | -24.8% | MNOV | |
| 52-Week Range Position | 63% ($13–$38) | 3% ($1–$4) | SRZN | |
| Beta / 30D Volatility | 1.29β · 73% Vol | 0.59β · 38% Vol | MNOV | |
| Unified Institutional Score | 36.0 / 100 (SELL) | 50.2 / 100 (HOLD) | MNOV | |
| Trailing 12M Revenue (USD) | $11M | $935,717 | Scale | |
| Gross Profit Margin (TTM) | N/A | 42.2% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 52.1x EV/Rev | N/M PEG · 42.5x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$31M ($95M Net Cash) | -$9.1M ($25M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
SRZN +17.61 pp
3M Horizon
SRZN +33.11 pp
6M Horizon
SRZN +14.36 pp
1Y Horizon
SRZN +119.2 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | SRZN Revenue | MNOV Revenue | SRZN Op. Margin | MNOV Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2012 | N/A | $0M | N/A | -1363.8% | MNOV |
| FY2021 | N/A | $0M | N/A | -253.0% | MNOV |
| FY2022 | $10M | N/A | -354.7% | N/A | SRZN |
| FY2023 | N/A | $0M | N/A | -990.0% | MNOV |
| FY2024 | $10M | N/A | -239.7% | N/A | SRZN |
| FY2025 | $0M | $0M | -1210.6% | -3242.5% | SRZN |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
SRZN
CONSOLIDATION
Current IV
72.0%
IV Percentile
13th %ile
Put/Call OI Skew
21.00x (Put-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact SRZN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
MNOV
UNCLASSIFIED
Current IV
140.1%
IV Percentile
50th %ile
Put/Call OI Skew
N/A
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact MNOV Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
SRZN Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
MNOV Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ SRZN vs MNOV Key Questions & Quantitative Answers
As of Nov 20, 2026, Surrozen, Inc. Common (SRZN) captures the overall head-to-head institutional edge over Medicinova, Inc. (MNOV) on higher Unified Composite conviction (36.0/100 SELL vs. 50.2/100 HOLD) after splitting the core matrix 4–5 (led by Growth & Scale, Options & Positioning), while MNOV wins 3–2 across the 6-pillar growth and valuation breakdown. SRZN trades at $28.46 (N/M Forward P/E, -485.4% operating margin) versus MNOV at $1.31 (8.5x Forward P/E, -1232.2% operating margin). Composite vs. Pillar Nuance: While MNOV currently prints a higher short-term Unified Composite Score (50.2/100 HOLD vs. SRZN 36.0/100 SELL), SRZN captures the overall institutional head-to-head verdict (4–5 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (-485.4% vs. -1232.2% operating margin) and revenue trajectory (+408.6% vs. +12.4% YoY). Technical & Structure Timing Caution: SRZN trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 47.2); meanwhile MNOV is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
SRZN leads the Growth & Scale pillar: SRZN posts +408.6% YoY revenue growth and -37.0% YoY earnings growth on $11M TTM revenue (N/A gross margin, -485.4% operating margin), compared with MNOV at +12.4% YoY revenue growth and +0.0% YoY earnings growth on $935,717 TTM revenue (42.2% gross margin, -1232.2% operating margin). Across the 6-period historical trajectory (FY2012 to FY2025), SRZN cumulative revenue shifted +0.0% while MNOV shifted N/A. In operating R&D and SG&A reinvestment, SRZN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MNOV.
MNOV screens cheaper on headline valuation multiples. SRZN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 52.1x EV/Revenue (unreported FCF margin), whereas MNOV trades at 8.5x Forward P/E, 8.5x Trailing P/E, N/M PEG, and 42.5x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SRZN (-62.8% ROE) versus MNOV (-24.8% ROE) capital efficiency.
In options market volatility and institutional positioning, SRZN carries 72.0% implied volatility (13th %ile, Compressed (<25th %ile)), a 21.00x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.29β · 73% Vol realized risk). By comparison, MNOV carries 140.1% implied volatility (50th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.59β · 38% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
MNOV vs SRZN · Reverse Pair
SRZN vs FTH
· Sector Peer
SRZN vs JSPR
· Sector Peer
SRZN vs TIL
· Sector Peer
MNOV vs ENTX
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma